Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Calithera Biosci Com (CALA)

Calithera Biosci Com (CALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Calithera: Q3 Earnings Snapshot AP - Mon Nov 14, 2022

Calithera: Q3 Earnings Snapshot

CALA : 0.0076 (unch)
Calithera Biosciences (CALA) Q2 2022 Earnings Call Transcript Motley Fool - Mon Aug 15, 2022

CALA earnings call for the period ending June 30, 2022.

CALA : 0.0076 (unch)
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 Globe Newswire - Mon Aug 8, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology...

CALA : 0.0076 (unch)
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences Globe Newswire - Wed Jul 13, 2022

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- --...

CALA : 0.0076 (unch)
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer Globe Newswire - Wed Jul 6, 2022

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06,...

CALA : 0.0076 (unch)
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma Globe Newswire - Thu Jun 23, 2022

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor...

CALA : 0.0076 (unch)
Calithera Biosciences Announces 1-for-20 Reverse Stock Split Globe Newswire - Tue Jun 14, 2022

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology...

CALA : 0.0076 (unch)
Calithera Biosciences (CALA) Q1 2022 Earnings Call Transcript Motley Fool - Wed May 11, 2022

CALA earnings call for the period ending March 31, 2022.

CALA : 0.0076 (unch)
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights Globe Newswire - Tue May 10, 2022

-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 ...

CALA : 0.0076 (unch)
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds Globe Newswire - Fri Apr 8, 2022

Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous...

CALA : 0.0076 (unch)

Barchart Exclusives

Buy the Dip in This Dividend Aristocrat for a Strong 2025 Barchart - Wed Nov 27, 6:30PM CST
McDonald's has faced challenges in 2024, including an E. coli outbreak, but is investing $100 million to recover and win back customers. With a strong brand, solid finances, and a clear growth strategy, the company's recent dip presents a rare chance to invest in a proven market leader with a long-term dividend growth streak. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot